Cross-Office Team Advises Relypsa in $1.53 Billion Acquisition by Galenica

Acquisition of Silicon Valley-based Relypsa by Switzerland's Galenica to help expand and enhance cardiology and gastroenterology medicines.

July 21, 2016

Switzerland-based Galenica Group and Redwood City, Calif.-based Relypsa, Inc. announced that the companies have entered into a definitive agreement under which Galenica will acquire Relypsa. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Subject to customary conditions, including the tender of the majority of the outstanding Relypsa shares and the expiration or earlier termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, the transaction is expected to close during the third quarter of 2016.

Latham & Watkins LLP represents Relypsa in the cross-border transaction with a corporate team led from the firm’s Silicon Valley office by partners Mark Roeder, Josh Dubofsky and Chad Rolston, with associates Saad Khanani, John Williams, Catherine Keller, Bret Stancil and Brandon Hartstein. Advice is also being provided on benefits and compensation matters by partner James Metz with associate Ashley Wagner; on antitrust matters by partner Joshua Holian with associate Patrick English; on intellectual property matters by partner Judith Hasko with counsel Geoffrey Kuziemko and associate Stephanie McHughen; on regulatory matters by partner John Manthei and associate Elizabeth Richards; and on tax matters by partner Kirt Switzer with associate Jessica Chen. All lawyers are based in Latham’s Silicon Valley office with the following exceptions: Mr. Holian and Ms. Chen in San Francisco; Mr. Manthei, Ms. Richards and Mr. English in Washington, D.C.; and Ms. McHughen in Los Angeles.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.